Muscle invasive bladder cancer: where is the field headed?

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. Ca A Cancer J Clinicians. 2022 Jan;72(1):7–33.
   PubMed Web of Science ®Google Scholar
• Nielsen ME, Smith AB, Meyer A-M, et al. Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006. Cancer. 2014;120(1):86–95. doi: 10.1002/cncr.28397
   PubMed Web of Science ®Google Scholar
• Alifrangis C, McGovern U, Freeman A, et al. Molecular and histopathology directed therapy for advanced bladder cancer. Nat Rev Urol. 2019 Aug;16(8):465–483.
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours. Eur Urol. 2016 Jul;70(1):106–119.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet (London, England). 2016 Dec 3;388(10061):2796–2810. doi: 10.1016/S0140-6736(16)30512-8
   PubMed Web of Science ®Google Scholar
• Magers MJ, Lopez-Beltran A, Montironi R, et al. Staging of bladder cancer. Histopathology. 2019 Jan;74(1):112–134.
   PubMed Web of Science ®Google Scholar
• Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013 Feb;63(2):234–241.
   PubMed Web of Science ®Google Scholar
• Halaseh SA, Halaseh S, Alali Y, et al. A review of the etiology and epidemiology of bladder cancer: all you need to know. Cureus. 2022 Jul;14(7):e27330.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003 Aug 28;349(9):859–866. doi: 10.1056/NEJMoa022148
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001 May;19(10):2638–2646.
   PubMed Web of Science ®Google Scholar
• Chang SS, Bochner BH, Chou R, et al. Treatment oF non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017 Sep 01;198(3):552–559.
   PubMed Web of Science ®Google Scholar
• Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. Ca A Cancer J Clinicians. 2020 Sep;70(5):404–423. doi: 10.3322/caac.21631
   PubMed Web of Science ®Google Scholar
• Thompson C, Joseph N, Sanderson B, et al. Tolerability of concurrent chemoradiation therapy with gemcitabine (GemX), with and without prior neoadjuvant chemotherapy, in muscle invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):732–739. doi: 10.1016/j.ijrobp.2016.11.040
   PubMed Web of Science ®Google Scholar
• International Collaboration of T, Medical Research Council Advanced Bladder Cancer Working P, European Organisation for R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29(16):2171–2177.
   PubMed Web of Science ®Google Scholar
• Pfister C, Gravis G, Fléchon A, et al. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol. 2022 Jun 20;40(18):2013–2022. doi: 10.1200/JCO.21.02051
   PubMed Web of Science ®Google Scholar
• Flaig TW, Tangen CM, Daneshmand S, et al. A Randomized Phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 May 1;27(9):2435–2441. doi: 10.1158/1078-0432.CCR-20-2409
   PubMed Web of Science ®Google Scholar
• Basile G, Bandini M, Gibb EA, et al. Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial. Clin Cancer Res. 2022 Oct 3;28(23):5107–5114. doi: 10.1158/1078-0432.CCR-22-2158
   PubMed Web of Science ®Google Scholar
• Powles T, Kockx M, Rodriguez-Vida A, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019 Nov 01;25(11):1706–1714.
   PubMed Web of Science ®Google Scholar
• Wei XX, McGregor BA, Lee RJ, et al. Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer:preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2. JCO. 2020 Feb 20;38(6_suppl):507–507.
   Web of Science ®Google Scholar
• Gao J, Navai N, Alhalabi O, et al. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 Dec;26(12):1845–1851.
   PubMed Web of Science ®Google Scholar
• Grande E, Guerrero F, Puente J, et al. DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature. J Clin Oncol. 2020;38(15_suppl):5012–5012. doi: 10.1200/JCO.2020.38.15_suppl.5012
   Google Scholar
• van Dorp J, Pipinikas C, Suelmann BBM, et al. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. Nat Med. 2023 Mar;29(3):588–592. doi: 10.1038/s41591-022-02199-y
   PubMed Web of Science ®Google Scholar
• Hoimes CJ, Adra N, Fleming MT, et al. Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188. J Clin Oncol. 2020;38(15_suppl):5047–5047. doi: 10.1200/JCO.2020.38.15_suppl.5047
   Google Scholar
• Kaimakliotis HZ, Adra N, Kelly WK, et al. Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of GU14-188. J Clin Oncol. 2020;38(15_suppl):5019–5019. doi: 10.1200/JCO.2020.38.15_suppl.5019
   Web of Science ®Google Scholar
• Rose TL, Harrison MR, Deal AM, et al. Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer. JCO. 2021 Oct 1;39(28):3140–3148. doi: 10.1200/JCO.21.01003
   Google Scholar
• Gupta S, Sonpavde G, Weight CJ, et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. J Clin Oncol. 2020;38(6_suppl):439–439. doi: 10.1200/JCO.2020.38.6_suppl.439
   Web of Science ®Google Scholar
• Galsky MD, Daneshmand S, Lewis SC, et al. Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2023;41(6_suppl):447–447. doi: 10.1200/JCO.2023.41.6_suppl.447
   PubMedGoogle Scholar
• Chanza NM, Carnot A, Barthelemy P, et al. 659MO Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC). Ann Oncol. 2021;32:S683.
   Google Scholar
• Martinez Chanza N, Carnot A, Barthélémy P, et al. Avelumab as the basis of neoadjuvant regimen in platinum-eligible and -ineligible patients with nonmetastatic muscle-invasive bladder cancer: AURA (Oncodistinct-004) trial. Am Soc Clin Oncol. 2022;40(16_suppl):4517–4517. doi: 10.1200/JCO.2022.40.16_suppl.4517
   Web of Science ®Google Scholar
• Petrylak DP, Flaig TW, Mar N, et al. Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. J Clin Oncol. 2022;40(6_suppl):435–435. doi: 10.1200/JCO.2022.40.6_suppl.435
   Web of Science ®Google Scholar
• Necchi A, Raggi D, Gallina A, et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020 Apr;77(4):439–446.
   PubMed Web of Science ®Google Scholar
• Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. 2018;36(34):3353–3360. doi: 10.1200/JCO.18.01148
   PubMed Web of Science ®Google Scholar
• Szabados B, Kockx M, Assaf ZJ, et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol. 2022 Aug;82(2):212–222.
   PubMed Web of Science ®Google Scholar
• Grivas P, Yin J, Koshkin VS, et al. PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2021;39(15_suppl):4518–4518. doi: 10.1200/JCO.2021.39.15_suppl.4518
   Web of Science ®Google Scholar
• Gao J, Siefker-Radtke AO, Navai N, et al. A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). J Clin Oncol. 2019;37(15_suppl):4551–4551. doi: 10.1200/JCO.2019.37.15_suppl.4551
   Web of Science ®Google Scholar
• van Dijk N, Gil-Jimenez A, Silina K, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med. 2020 Dec;26(12):1839–1844.
   PubMed Web of Science ®Google Scholar
• High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2). Ann Oncol. 2021;32(suppl_5):S1283–S1346. doi: 10.1016/annonc/annonc741
   Web of Science ®Google Scholar
• Guercio BJ, Pietzak EJ, Brown S, et al. Neoadjuvant nivolumab (N) ± ipilimumab (I) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2022;40(6_suppl):498–498. doi: 10.1200/JCO.2022.40.6_suppl.498
   Web of Science ®Google Scholar
• Alva A, Csőszi T, Ozguroglu M, et al. LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. Ann Oncol. 2020;31:S1155. doi: 10.1016/j.annonc.2020.08.2252
   Google Scholar
• Galsky MD, Arija JA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet (London, England). 2020 05;395(10236):1547–1557. doi: 10.1016/S0140-6736(20)30230-0
   PubMed Web of Science ®Google Scholar
• Powles T, van der Heijden MS, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020 12;21(12):1574–1588. doi: 10.1016/S1470-2045(20)30541-6
   PubMed Web of Science ®Google Scholar
• Brown J, Kaimakliotis HZ, Kelly WK, et al. HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer. J Clin Oncol. 2023;41(6_suppl):448–448. doi: 10.1200/JCO.2023.41.6_suppl.448
   Google Scholar
• Galsky MD, Daneshmand S, Chan KG, et al. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257. J Clin Oncol. 2021;39(15_suppl):4503–4503. doi: 10.1200/JCO.2021.39.15_suppl.4503
   Web of Science ®Google Scholar
• Geynisman DM, Abbosh P, Ross EA, et al. A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN). J Clin Oncol. 2023;41(6_suppl):438–438. doi: 10.1200/JCO.2023.41.6_suppl.438
   Google Scholar
• Cathomas R, Rothschild S, Hayoz S, et al. Safety and efficacy of perioperative cisplatin/gemcitabine (cis/gem) and durvalumab (durva) for operable muscle-invasive urothelial carcinoma (MIUC): SAKK 06/17. J Clin Oncol. 2021;39(6_suppl):430–430. doi: 10.1200/JCO.2021.39.6_suppl.430
   Web of Science ®Google Scholar
• Cathomas R, Rothschild S, Hayoz S, et al. Perioperative chemoimmunotherapy with durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): Primary analysis of the single arm phase II trial SAKK 06/17. J Clin Oncol. 2022;40(16_suppl):4515–4515. doi: 10.1200/JCO.2022.40.16_suppl.4515
   Web of Science ®Google Scholar
• Balar AV, McGregor BA, Rosenberg JE, et al. EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors. J Clin Oncol. 2021;39(6_suppl):394–394. doi: 10.1200/JCO.2021.39.6_suppl.394
   Web of Science ®Google Scholar
• Hoimes CJ, Flaig TW, Milowsky MI, et al. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023 Jan 1;41(1):22–31.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):525–537. doi: 10.1016/S1470-2045(21)00004-8
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang J, Ruan W, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J Clin Investig. 2020 Dec 1;130(12):6278–6289. doi: 10.1172/JCI139597
   PubMed Web of Science ®Google Scholar
• Powles T, Assaf Z, Davarpanah N, et al. 1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy. Ann Oncol. 2020;31:S1417. doi: 10.1016/j.annonc.2020.10.486
   PubMed Web of Science ®Google Scholar
• Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021 Jul;595(7867):432–437.
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Witjes JA, Gschwend J, et al. First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC). J Clin Oncol. 2021;39(6_suppl):391–391. doi: 10.1200/JCO.2021.39.6_suppl.391
   Web of Science ®Google Scholar
• Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021 Jun 3;384(22):2102–2114. doi: 10.1056/NEJMoa2034442
   PubMed Web of Science ®Google Scholar
• Giacalone NJ, Shipley WU, Clayman RH, et al. Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience. Eur Urol. 2017 Jun;71(6):952–960.
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Foroudi F, Lawrentschuk N, et al. Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502). J Clin Oncol. 2020;38(6_suppl):485–485. doi: 10.1200/JCO.2020.38.6_suppl.485
   Web of Science ®Google Scholar
• Balar AV, Milowsky MI, O’Donnell PH, et al. Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial. J Clin Oncol. 2021;39(15_suppl):4504–4504. doi: 10.1200/JCO.2021.39.15_suppl.4504
   Google Scholar
• Singh P, Efstathiou JA, Tangen C, et al. INTACT (S/N1806) phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle-invasive bladder cancer: Safety update on first 73 patients. Am Soc Clin Oncol. 2021;39(6_suppl):428–428. doi: 10.1200/JCO.2021.39.6_suppl.428
   Web of Science ®Google Scholar
• Joshi M, Kaag M, Tuanquin L, et al. Phase II clinical study of concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results for primary analyses and survival. BTCRC-GU15-023. J Clin Oncol. 2021;39(6_suppl):398–398. doi: 10.1200/JCO.2021.39.6_suppl.398
   Web of Science ®Google Scholar
• Vaishampayan U, Heilbrun L, Vaishampayan N, et al. 776P Phase II trial of concurrent nivolumab in urothelial bladder cancer with radiation therapy in localized/locally advanced disease for chemotherapy ineligible patients [NUTRA trial]. Ann Oncol. 2020;31:S596. doi: 10.1016/j.annonc.2020.08.848
   Web of Science ®Google Scholar
• Vazquez-Estevez S, Fernandez-Calvo O, Bonfill-Abella T, et al. Efficacy and safety of atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer: An interim analysis of the ATEZOBLADDERPRESERVE phase II trial (SOGUG-2017-A-IEC(VEJ)-4). J Clin Oncol. 2022;40(16_suppl):4588–4588. doi: 10.1200/JCO.2022.40.16_suppl.4588
   Web of Science ®Google Scholar
• Muro X, Valderrama BP, Medina A, et al. Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial. JCO. 2021;39(15_suppl):4505–4505. doi: 10.1200/JCO.2021.39.15_suppl.4505
   Web of Science ®Google Scholar
• Gupta S, Grass GD, Maughan BL, et al. NEXT: A single-arm, phase 2, open-label study of adjuvant nivolumab after completion of chemo-radiation therapy in patients with localized muscle-invasive bladder cancer. J Clin Oncol. 2022;40(6_suppl):506–506. doi: 10.1200/JCO.2022.40.6_suppl.506
   Web of Science ®Google Scholar
• Liu S, Chen X, Lin T. Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives. J Adv Res. 2022 Jul;39:187–202. doi: 10.1016/j.jare.2021.11.010
   PubMed Web of Science ®Google Scholar
• Rodriguez-Moreno JF, Velasco G, Fernandez IB, et al. Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial. J Clin Oncol. 2020;38(6_suppl):542–542. doi: 10.1200/JCO.2020.38.6_suppl.542
   Web of Science ®Google Scholar
• Galsky MD, Sfakianos JP, Ye D-W, et al. ANTICIPATE: A phase I/II, open-label, multicenter study to evaluate the safety and efficacy of oral APL-1202 in combination with tislelizumab compared to tislelizumab alone as neoadjuvant therapy (NAC) in patients with muscle invasive bladder cancer (MIBC). J Clin Oncol. 2022;40(16_suppl):TPS4613–TPS4613. doi: 10.1200/JCO.2022.40.16_suppl.TPS4613
   Web of Science ®Google Scholar
• Grivas P, Heijden MSVD, Necchi A, et al. PIVOT IO 009: A phase 3, randomized study of neoadjuvant and adjuvant nivolumab (NIVO) plus bempegaldesleukin (BEMPEG; NKTR-214) versus NIVO alone versus standard of care (SOC) in patients (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin (cis)-ineligible. J Clin Oncol. 2022;40(6_suppl):TPS596–TPS596.
   Web of Science ®Google Scholar
• Gupta S, Gibb E, Sonpavde GP, et al. Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy. J Clin Oncol. 2022;40(6_suppl):528–528. doi: 10.1200/JCO.2022.40.6_suppl.528
   Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018 02;554(7693):544–548. doi: 10.1038/nature25501
   PubMed Web of Science ®Google Scholar
• Miron B, Hoffman-Censits JH, Anari F, et al. Defects in DNA repair genes confer improved long-term survival after cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol Oncol. 2020 Aug;3(4):544–547.
   PubMed Web of Science ®Google Scholar
• Plimack ER, Tangen C, Plets M, et al. S1314 correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): Implications for bladder preservation. J Clin Oncol. 2022;40(16_suppl):4581–4581. doi: 10.1200/JCO.2022.40.16_suppl.4581
   Web of Science ®Google Scholar
• Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discovery. 2014 Oct;4(10):1140–1153.
   PubMed Web of Science ®Google Scholar
• Becker REN, Meyer AR, Brant A, et al. Clinical Restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2021 Mar;79(3):364–371.
   PubMed Web of Science ®Google Scholar
• Geynisman DM, Abbosh P, Ross EA, et al. A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN). J Clin Oncol. 2023 Feb 20;41(6_suppl): 438–438 .
   Google Scholar
• Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2018;36(34): 3353–3360.
   PubMed Web of Science ®Google Scholar
• Kamoun A, de Reyniès A, Allory Y, et al. A Consensus Molecular Classification Of Muscle-invasive Bladder Cancer. Eur Urol. 2020 Apr;77(4):420–433.
   PubMed Web of Science ®Google Scholar
• Seiler R, Ashab HAD, Erho N, et al. Impact of MOLECULAR SUBTYPES IN MUSCLE-INVASIVE BLADDER CANCER ON PREDICTING RESPONSE AND SURVIVAL AFTER NEOADJUVANT CHEMOTHERApy. Eur Urol. 2017 10;72(4):544–554. doi: 10.1016/j.eururo.2017.03.030
   PubMed Web of Science ®Google Scholar
• Necchi A, Raggi D, Gallina A, et al. Impact of Molecular Subtyping And Immune Infiltration On Pathological Response And Outcome Following Neoadjuvant Pembrolizumab In Muscle-invasive Bladder Cancer. Eur Urol. 2020 Jun;77(6):701–710.
   PubMed Web of Science ®Google Scholar
• Liakou CI, Kamat A, Tang DN, et al. CTLA-4 blockade increases IFNγ-producing CD4 + ICOS hi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci, USA. 2008 Sep 30;105(39):14987–14992. doi: 10.1073/pnas.0806075105
   PubMed Web of Science ®Google Scholar
• Cattaneo L, Lagano V, Carpenito L, et al. Digital evaluation of tumor microenvironment immune markers pre- and post-neoadjuvant pembrolizumab in muscle-invasive bladder cancer (Pure-01 trial: An open label, single arm, phase II study). J Clin Oncol. 2023;41(6_suppl):541–541. doi: 10.1200/JCO.2023.41.6_suppl.541
   PubMedGoogle Scholar
• Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. JCO. 2019 Jun;37(18):1547–1557.
   PubMed Web of Science ®Google Scholar
• Dyrskjøt L, Laliotis MD, George P, et al. Utility of ctDNA in predicting outcome and pathological complete response in patients with bladder cancer as a guide for selective bladder preservation strategies. Am Soc Clin Oncol. 2023;41(6_suppl):563–563. doi: 10.1200/JCO.2023.41.6_suppl.563
   Google Scholar
• Zhang J, Zhang R, Xie F, et al. Comparative analysis of urinary and tissue tumor DNA in muscle-invasive bladder cancer by boosted whole-exome sequencing. Ann Oncol. 2022;33(suppl_7):S27–S54. doi: 10.1016/j.annonc.2022.07.138
   Web of Science ®Google Scholar
• Chauhan PS, Shiang A, Alahi I, et al. Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients. NPJ Precis Oncol. 2023 Jan 19;7(1):6.
   PubMed Web of Science ®Google Scholar
• Zibelman M, Asghar AM, Parker DC, et al. Cystoscopy and systematic bladder tissue sampling in predicting pt0 bladder cancer: a prospective trial. J Urol. 2021 Jun;205(6):1605–1611.
   PubMed Web of Science ®Google Scholar
• Panebianco V, Narumi Y, Altun E, et al. Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (vesical imaging-reporting and data system). Eur Urol. 2018 Sep;74(3):294–306.
   PubMed Web of Science ®Google Scholar